BCG: A Note of Caution

Publisher Website
Google Scholar
Abstract
An enthusiastic lay press has studded the vocabulary of the general public with immunologic jargon, frequently keeping patients and physicians equally abreast of the promising results of experimental tumor immunotherapy. There is little difficulty understanding the excitement generated in a cancer-prone population by the experimental results to date, particularly with reference to BCG. In animal tumor systems, for example, investigations have shown that prophylactic BCG immunization can definitely suppress development of transplanted antigenic tumors,1 that established cutaneous tumors (and in some cases lymph-node metastases) regress after intralesional BCG,2 and that implants of pulmonary sarcomas may be suppressed by intravenous BCG . . .

This publication has 0 references indexed in Scilit: